Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine
|ClinicalTrials.gov Identifier: NCT00500721|
Recruitment Status : Completed
First Posted : July 13, 2007
Last Update Posted : April 14, 2008
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: HCV-796 Drug: Desipramine||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||22 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label, Single-Dose Desipramine, Multiple-Dose HCV-796, Sequential 3-Period Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine|
|Study Start Date :||June 2007|
|Actual Primary Completion Date :||August 2007|
|Actual Study Completion Date :||August 2007|
Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.
Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.
Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10.
- Pharmacokinetic (PK) [ Time Frame: 21 days ]
- Safety [ Time Frame: 29 days ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00500721
|United States, Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19148|
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|